Medical AI can’t do much without info-sharing patients—and younger generations aren’t thrilled to be asked

To feed medical AI the massive volumes of clinical data it needs to succeed, researchers must offer patients individualized options for sharing personal health information.

The demand for such tailored consent is strongest among younger generations, further pressing the need to speed the evolution of PHI policies to propel AI development.

So report researchers in Canada who surveyed 222 patients and had their findings published March 24 in BMC Medical Ethics.  

Senior author Fei-Fei Liu, MD, of the University of Toronto and colleagues found 83% of all respondents having no qualms about sharing PHI with researchers at their own hospital.

However, 13% of those aged 49 and younger said they’d be uncomfortable with the prospect while only 2% of those 50 and older had similar misgivings.

Other key findings drawn from the representative sampling:

  • 70% of patients expect to be notified of study results.
  • 63% want to be asked for permission before being entered into a contact pool. The younger cohort want more of a say (76%).
  • 61% want the ability to track use of their PHI, and the younger patients comprise the bulk of this subgroup.
  • 56% of all patients are OK giving broad consent for PHI sharing with researchers, while 38% prefer specific consent and 6% would not consent at all.  

Meanwhile 51% of the 222 indicated feeling uncomfortable about sharing PHI with commercial enterprises, but 27% were fine with the idea and 22% were neutral.

“We would be remiss to allow these results to reverberate in an esoteric echo chamber; further work must uncover strategies to translate these findings into effective policy changes,” Liu and co-authors comment in their discussion section. “While this seems like a vast undertaking, the very technological advancements that have prompted the need for massive volumes of PHI can no doubt be applied to the design and implementation of modern consent platforms that exemplify a respect for well-identified patient values and preferences.”

The study is available in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.